TCGA-CN-5374-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.39543379
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.310
- SPERMATOGENESIS+0.310
- G2M_CHECKPOINT+0.230
- ALLOGRAFT_REJECTION+0.210
- KRAS_SIGNALING_DN+0.120
- BILE_ACID_METABOLISM+0.070
- PEROXISOME+0.060
- WNT_BETA_CATENIN_SIGNALING+0.040
- FATTY_ACID_METABOLISM-0.040
- MITOTIC_SPINDLE-0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.540
- PROTEIN_SECRETION-0.510
- TNFA_SIGNALING_VIA_NFKB-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- TGF_BETA_SIGNALING-0.420
- MTORC1_SIGNALING-0.390
- HYPOXIA-0.380
- MYC_TARGETS_V2-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.886 |
| 2 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.874 |
| 3 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.874 |
| 4 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.871 |
| 5 | MDT-AP-1162 | Med | Medulloblastoma | 0.869 |
| 6 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.868 |
| 7 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.864 |
| 8 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.853 |
| 9 | TCGA-CR-7404-01A-11R-2132-07 | — | — | 0.847 |
| 10 | TCGA-QK-AA3J-01A-11R-A39I-07 | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |